Tildrakizumab in the treatment of moderate‐to‐severe hidradenitis suppurativa

Kok, Yonatan; Nicolopoulos, Jenny; Howard, Anne; Varigos, George; Kern, Johannes S.; Dolianitis, Con

doi:10.1111/ajd.13377

Cited by 19 publications

(26 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, long‐term clinical responses range only from 52 to 57% 2 . Tildrakizumab (anti‐IL‐23), 3 guselkumab (anti‐IL‐23) 4 and ustekinumab (anti‐IL‐12/23) 5 have been successfully used in HS.…”

Section: Patient 1 Patientmentioning

confidence: 99%

“…2 Clinically, HPMH is characterized by red-brown papules on the face, hands, forearms and legs (Figure 1a), and usually develops in childhood or early adolescence; lesions do not tend to regress with age. [1][2][3] Here, we report a gain-of-function missense mutation in the platelet-derived growth factor receptor beta (PDGFRB) gene as a possible cause for HPMH in the original pedigree reported in 1988. 1 A 30-year-old woman (individual IV.3 in Figure 1b) developed red skin tumours ranging in size from 2 mm to 10 mm.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

et al. 2021

View full text Add to dashboard Cite

DEAR EDITOR, Hidradenitis suppurativa (HS) is a relapsing inflammatory skin disease. The cytokines interleukin (IL)-1b, IL-12, IL-23, IL-17 and tumour necrosis factor (TNF)-a are involved in the inflammatory process. 1 The only approved drug for the treatment of moderate-to-severe cases is adalimumab (a TNF-a inhibitor). However, long-term clinical responses range only from 52 to 57%. 2 Tildrakizumab (anti-IL-23), 3 guselkumab (anti-IL-23) 4 and ustekinumab (anti-IL-12/23) 5 have been successfully used in HS.Risankizumab is a humanized IgG1 monoclonal antibody selective to IL-23. It is currently approved for the treatment of moderate-to-severe plaque psoriasis in adults. 6 We describe two patients with severe Hurley Stage III HS, successfully treated with risankizumab:Patient 1 was a 39-year-old woman, a nonsmoker with a body mass index (BMI, kg m -2 ) of 28Á9. Her medical history included depression and multiple sclerosis (MS). Her mother and grandfather have been treated for HS. Historically, she was treated with systemic azithromycin, doxycycline, clindamycin, rifampicin, isotretinoin and, lastly, adalimumab (40 mg per week subcutaneously). Three months after starting adalimumab, she achieved a Hidradenitis Suppurativa Clinical Response (HiSCR). Loss of response (LoR) was observed after 20 months and consequently adalimumab was discontinued

show abstract

Section: Patient 1 Patientmentioning

confidence: 99%

mentioning

confidence: 99%

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a recent case series, involving 5 moderate-to-severe HS patients (40% female, 2 of whom had received prior anti-TNF-α therapy) treated with 100 mg tildrakizumab at weeks 0 and 4 and 200 mg every 4 weeks thereafter, an improvement in abscess and nodule count was demonstrated in all HS patients at week 8 compared to baseline (at week 20, 2 patients reported ongoing improvement). Tildrakizumab therapy was well-tolerated [ 256 ]. Furthermore, the researchers reported the efficacy of tildrakizumab in significantly reducing mean abscess and nodule count at month 15 (from baseline) in 9 moderate-to-severe HS patients (4 of whom started with 200 mg every 4 weeks from baseline).…”

Section: (New Medical) Therapeutical Approaches In Hsmentioning

confidence: 99%

Insights into the Pathogenesis of HS and Therapeutical Approaches

et al. 2021

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a debilitating, chronic, (auto)inflammatory disease primarily affecting apocrine gland-rich areas of the body. Although pathogenic mechanisms responsible for HS have not yet been fully elucidated, it is a multifactorial process whose main target is the terminal follicle. The role of the inflammatory process (and consequently of cytokine milieu) and of several other factors (genetics, lifestyle, hormonal status, microbiome, innate and adaptive immune systems) involved in HS pathogenesis has been investigated (and often defined) over the years with a view to transferring research results from bench to bedside and describing a unique and universally accepted pathogenetic model. This review will update readers on recent advances in our understanding of HS pathogenesis and novel (potential) medical therapies for patients with moderate-to-severe HS.

show abstract

“…Specifically, 100 mg of tildrakizumab was injected in 5 HS patients at weeks 0 and 4, followed by tildrakizumab 200 mg treatment every 4 weeks thereafter. All patients showed significant improvements in abscess and nodule counts; 4 patients had improvements in the Dermatology Life Quality Index (DLQI), and three patients experienced a reduction in pain symptoms ( 162 ). Tildrakizumab was also recently subcutaneously injected for the treatment-resistant lesions of lupus tumidus on the face.…”

Section: Off-label Use Of Il-23 Inhibitors Including Tildrakizumabmentioning

confidence: 99%

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

et al. 2021

View full text Add to dashboard Cite

Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on the extent, anatomical locations involved and functional impairment level. Targeting cytokines or their cognate receptors that are involved in disease pathogenesis such as IL-12/23 (i.e., targeting the IL-12p40 subunit shared by these cytokines), IL-17A, IL-17F, IL-17RA, and TNF-α using biologic agents emerged in recent years as a highly effective therapeutic option for patients with moderate-to-severe disease. This review provides an overview of the important role of IL-23 signaling in the pathogenesis of psoriasis. We describe in detail the available IL-23 inhibitors for chronic plaque psoriasis. The efficacy, pharmacokinetic properties, and the safety profile of one of the most recent IL-23 biologic agents (tildrakizumab) are evaluated and reviewed in depth.

show abstract

Tildrakizumab in the treatment of moderate‐to‐severe hidradenitis suppurativa

Cited by 19 publications

References 6 publications

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

Insights into the Pathogenesis of HS and Therapeutical Approaches

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

Contact Info

Product

Resources

About